A large study that investigates just what keeps our brains sharp as we age and what contributes to cognitive decline has been launched by researchers from Washington University School of Medicine in St. Louis, Harvard University/Massachusetts General Hospital, the University of Minnesota Medical School and the University of California Los Angeles (UCLA). Known as the Adult Aging Brain Connectome study, the project is funded by a $33.1 million grant from the National Institute on Aging, part of the National Institutes of Health (NIH).
- NIH/National Institute on Aging
First study on how a natural plant extract of a particular kind of wormwood, Artemisia scoparia, could lead to longer lifespans, including potentially for humans. Key lies in enhanced metabolic health.
- Journal of Gerontology
Cantex Pharmaceuticals, Inc., based in Weston, FL, has licensed IP from Harvard University to develop a repurposed drug identified by the Wyss Institute into a treatment for COVID-19 and other inflammatory lung diseases. Cantex Pharmaceuticals, Inc., based in Weston, FL, has licensed IP from Harvard University to develop a repurposed drug identified by the Wyss Institute into a treatment for COVID-19 and other inflammatory lung diseases. The drug, azeliragon, has already demonstrated exceptional safety in previous clinical trials involving more than 2,000 patients, and data from the Wyss Institute's Human Lung Alveolus Chip showed that it significantly blocks the production of inflammation-causing cytokines by inhibiting a protein called RAGE. Following submission of a pre-IND meeting request to the FDA, Cantex is planning to initiate a Phase 2 clinical trial in patients hospitalized with severe COVID later this year.
Gut bacteria brew all sorts of chemicals, but we don’t know what most of them do. A new study suggests that one such compound, previously linked to cancer, may serve as a bizarre weapon in microbial skirmishes.
Patients treated for Merkel cell carcinoma (MCC) face a five-year recurrence rate of 40%—markedly higher than the recurrence rates for melanoma and other skin cancers, according to research published today in JAMA Dermatology. Additionally, in the study cohort of more than 600 patients, 95% of MCC recurrences happened in the first three years, suggesting that surveillance efforts should be focused on that span the authors wrote.
- JAMA Dermatology
- NIH/National Cancer Institute, MCC Patient Gift Fund, Prostate Cancer Foundation
A new analysis of human remains that were buried in African archaeological sites has produced the earliest DNA from the continent, telling a fascinating tale of how early humans lived, traveled and even found their significant others.